KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EBIT: 2015-2025

Historic EBIT for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $163.1 million.

  • BeOne Medicines' EBIT rose 235.63% to $163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.7 million, marking a year-over-year increase of 120.94%. This contributed to the annual value of -$568.2 million for FY2024, which is 52.95% up from last year.
  • BeOne Medicines' EBIT amounted to $163.1 million in Q3 2025, which was up 85.60% from $87.9 million recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' EBIT peaked at $190.6 million during Q4 2021, and registered a low of -$474.8 million during Q2 2021.
  • Moreover, its 3-year median value for EBIT was -$120.3 million (2024), whereas its average is -$137.6 million.
  • Per our database at Business Quant, BeOne Medicines' EBIT tumbled by 731.76% in 2022 and then spiked by 235.63% in 2025.
  • BeOne Medicines' EBIT (Quarterly) stood at $190.6 million in 2021, then plummeted by 345.92% to -$468.6 million in 2022, then grew by 18.10% to -$383.8 million in 2023, then surged by 79.31% to -$79.4 million in 2024, then skyrocketed by 235.63% to $163.1 million in 2025.
  • Its EBIT stands at $163.1 million for Q3 2025, versus $87.9 million for Q2 2025 and $11.1 million for Q1 2025.